Zydus Lifesciences Limited — Updates, 19-12-2024: Press Release

Zydus Lifesciences Limited has received final approval from the USFDA for the manufacturing of Lidocaine and Prilocaine Cream USP, 2.5%/2.5%, a topical anesthetic used for local analgesia and minor surgeries. This approval allows Zydus to produce the cream at its facility in Changodar, Ahmedabad. The product has annual sales of approximately USD 22.05 million in the U.S., indicating a significant market opportunity. With this approval, Zydus now boasts a total of 412 approvals, having filed over 473 Abbreviated New Drug Applications (ANDAs) since FY 2003-04. This development enhances Zydus's portfolio and positions the company for further growth in the competitive pharmaceutical landscape. Investors should view this as a positive development, underscoring Zydus's commitment to expanding its product offerings and market reach.